indacaterol/glycopyrronium/mometasone / Qilu Pharma - LARVOL DELTA

Safety and Effectiveness of Indacaterol/Glycopyrronium/Mometasone Dry Powder Inhaler in Asthma: A Prospective Multicenter Phase IV Study. (PubMed, J Assoc Physicians India) - "Once-daily IND/GLY/MF DPI demonstrated a favorable safety profile and significant, sustained clinical benefits in adults with asthma inadequately controlled on ICS-LABA therapy. The triple combination provided rapid onset and sustained improvement in asthma control and lung function, with excellent adherence and tolerability in real-world Indian clinical practice. These findings support IND/GLY/MF as an effective and practical single-inhaler triple therapy option for optimized asthma management."

Journal • P4 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases